semaglutide cardiac protection FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Semaglutide approved for cardiovascular disease

Every patient receives structured clinical monitoring throughout the titration process and beyond

The most common sleep-related effects include mild insomnia during dose escalation (affecting roughly 8% of users) and occasional vivid dreams, both of which typically resolve within 4 to 6 weeks

Melanocortin 4 receptors (MC4Rs) are also found in the brain and play a role in appetite regulation

(In the current analysis, Al-Aly found that people taking the drugs had a 12% lower risk of the neurodegenerative disorder.) Many tissues in the body have receptors for GLP-1, a hormone, which explains its multiplicity of health effects

Head-to-head context No large randomized trial has directly compared tirzepatide to liraglutide head-to-head